Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 4Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Glioblastoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Breast Neoplasms 2Advanced Solid Tumor 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Spinal Cord Neoplasms 1Spinal Cord Compression 1Primary Myelofibrosis 1Peripheral Lung Tumor 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Melanoma 1

Interventions

Carboplatin 9pembrolizumab 8Paclitaxel 8Cisplatin 8Radiotherapy, Intensity-Modulated 6Magnetic Resonance Spectroscopy 6Gemcitabine 5fludarabine 4Specimen Handling 4Pemetrexed 4Nivolumab 4Cyclophosphamide 4trebananib 3osimertinib 3liposomal doxorubicin 3Radiotherapy 3Interleukin-2 3Fluorouracil 3Docetaxel 3DNA 3volociximab 2poly ICLC 2lenvatinib 2fludarabine phosphate 2Sorafenib 2Radiosurgery 2Midazolam 2Capecitabine 2Biopsy 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma × Therapeutics × Clear all
NCT02587819 2016-04-14

Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment

Biosceptre

Phase 1 Completed
21 enrolled 9 charts
Tumor-Agnostic

Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡